Girard Partners LTD. cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 8.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 61,507 shares of the company’s stock after selling 5,418 shares during the period. Johnson & Johnson accounts for approximately 1.5% of Girard Partners LTD.’s holdings, making the stock its 17th biggest holding. Girard Partners LTD.’s holdings in Johnson & Johnson were worth $7,957,000 at the end of the most recent quarter.
A number of other institutional investors have also added to or reduced their stakes in JNJ. WoodTrust Financial Corp raised its position in shares of Johnson & Johnson by 4.2% in the 3rd quarter. WoodTrust Financial Corp now owns 46,335 shares of the company’s stock valued at $5,995,000 after acquiring an additional 1,848 shares during the period. Park Avenue Securities LLC acquired a new stake in Johnson & Johnson during the 3rd quarter worth approximately $2,939,000. Billeaud Capital Management Inc. raised its holdings in Johnson & Johnson by 0.4% during the 2nd quarter. Billeaud Capital Management Inc. now owns 44,014 shares of the company’s stock worth $6,130,000 after buying an additional 169 shares during the period. Meeder Asset Management Inc. raised its holdings in Johnson & Johnson by 11.1% during the 2nd quarter. Meeder Asset Management Inc. now owns 109,690 shares of the company’s stock worth $15,277,000 after buying an additional 10,927 shares during the period. Finally, Lucia Wealth Services LLC raised its holdings in Johnson & Johnson by 2.1% during the 3rd quarter. Lucia Wealth Services LLC now owns 131,950 shares of the company’s stock worth $17,072,000 after buying an additional 2,744 shares during the period. Institutional investors own 72.25% of the company’s stock.
Several analysts have commented on JNJ shares. Bank of America restated a “hold” rating and set a $150.00 target price on shares of Johnson & Johnson in a report on Tuesday, July 16th. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, July 16th. Raymond James dropped their target price on shares of Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. Credit Suisse Group raised their target price on shares of Johnson & Johnson from $158.00 to $163.00 in a report on Thursday, October 24th. Finally, Zacks Investment Research upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $142.00 target price on the stock in a report on Thursday, October 17th. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Johnson & Johnson currently has a consensus rating of “Buy” and a consensus price target of $151.64.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share for the quarter, topping the consensus estimate of $2.00 by $0.12. The company had revenue of $20.73 billion during the quarter, compared to analysts’ expectations of $20.14 billion. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. The business’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period last year, the business earned $2.05 EPS. On average, analysts anticipate that Johnson & Johnson will post 8.65 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, November 25th. This represents a $3.80 annualized dividend and a dividend yield of 2.86%. Johnson & Johnson’s dividend payout ratio is currently 46.45%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: What is Depreciation?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.